NetScientific PLC (LON:NSCI) said its portfolio company, ProAxsis, will present data on its NEATstik test to the American Thoracic Society (ATS) conference in San Diego.
The AIM-listed company, which commercialises healthcare IPs, said ProAxsis’ data on NEATstix, its novel point of care test for monitoring active neutrophil elastase (NE) in chronic respiratory disease, demonstrated that it can identify patients with elevated active NE concentrations which could be related to bacterial infections which lead to the conditions.
READ: NetScientific says portfolio company, Vortex BioSciences, to present “compelling new data” at AACR
The group added that ProAxsis would present data on a new high sensitivity version of the assay to the ATS conference, to take place between 19-24 May, which it says provides further validation and underscores the emerging importance of neutrophil elastase as a leading indicator of infection and inflammation in patients with cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD) and bronchiectasis, and an important drug target.
Francois Martelet, chief executive of NetScientific and chairman of ProAxsis, said: "The data presented at ATS show that NEATstik can play a role in identifying the role played by a bacterial infection in COPD.
He added: “We are very pleased to see continued validation of the role of neutrophil elastase in respiratory diseases, and excited about presenting data at the prestigious ATS Annual Conference.”
In early morning trading Wednesday, NetScientific shares were steady at 47.5p.